Bayer(US:BAYRY) 生物世界·2025-07-08 00:01Core Viewpoint - Bayer is committed to enhancing its focus and resource investment in China's innovation ecosystem, aiming to collaborate with local innovators to discover the next significant breakthroughs in drug development [1]. Group 1: Competition Announcement - Bayer China has officially launched the "Co-Creation New Drug" competition, inviting Chinese innovators and biotechnology companies to submit and showcase their innovative research pipelines, drug molecules, or new technologies with breakthrough potential [1]. Group 2: Target Therapeutic Areas - The competition focuses on several key therapeutic areas, including: - Precision Oncology - Precision Cardiorenal Diseases - Immunology & Inflammation [2]. Group 3: Research Pipeline Stages - The competition accepts submissions at various stages of the research pipeline, ranging from early pre-clinical candidate compounds (pre-PCC) to clinical proof of concept (clinical PoC) [2]. Group 4: Drug Molecule Forms - Eligible drug molecule forms include: - Biologics - Small molecules (SMOL) - Conjugated drugs (XDC) - Genetic medicine - Small nucleic acid drugs (siRNA) - Molecular glue - Other platform technologies [3]. Group 5: Evaluation Criteria - Submissions will be evaluated by a review committee composed of Bayer China's and global R&D and business development experts based on innovation level, key data, advancement speed, and alignment with Bayer's R&D strategy [4].